Erasca is a developer of oncology drugs intended provide precision oncology options.
Erasca's mission is to erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure.
Erasca was founded in 2018 by Jonathan E. Lim. The company is headquartered in San Diego, California.
Erasca has assembled a robust pipeline of targeted therapies directed at undisclosed targets through in-house drug discovery, as well as active pipeline expansion through collaborations with world-class academic and biopharmaceutical organizations.
Erasca is backed by ARCH Venture Partners, Cormorant Asset Management, EDBI, Invus, City Hill Ventures, Partner Fund Management, OrbiMed, Colt Ventures and others. The company raised an additional $36M to its Series B on Aug 31, 2020. The funding comes as an extension of its $200M Series B, to bring the round total to $236M. This additional financing als brings the total amount raised by Erasca to $300M to date.